DRIHEALTHCARE

ADVANCING SCIENCE

in the Fast-Growing Pharmaceutical and Biotechnology Sector

January 2023

Disclaimer

Certain statements made in this presentation, including responses to questions, may contain forward-looking statements within the meaning of the safe harbor provisions of Canadian provincial securities laws. Forward-looking statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements.

For additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, please consult the MD&A, the Risk Factors section of the Annual Information Form and DRI Healthcare Trust's other filings with Canadian securities regulators. DRI Healthcare Trust does not undertake to update any forward-looking statements; such statements speak only as of the date made.

This presentation also makes reference to certain non-GAAP financial measures including Total Cash Receipts and certain non-GAAP ratios including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized measures under IFRS and are therefore unlikely to be comparable to similar financial measures disclosed by other issuers. Rather, these measures and ratios are provided as additional information to complement those IFRS measures by providing further understanding of DRI Healthcare Trust's financial performance from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of financial information reported under IFRS.

All dollar figures in this presentation are stated in US dollars.



Low risk exposure to rapid biopharma growth


34-year¹ History

\$2.5B+ Capital deployed

68 Royalty acquisitions

DRIHEALTHCARE

6,500+ Royalty opportunities in proprietary database



12 months ended September 30, 2022

\$93M Total Income

\$87M Adjusted EBITDA

86% Adjusted EBITDA Margin

\$375M³ Capital deployed since IPO

Therapeutic area allocation based on net book value pro forma as at September 30, 2022.

Diverse portfolio with large pharmaceutical company characteristics

Historical data includes activities prior to establishment of DRI Healthcare Trust in February 2021

2. Excludes secured loan to CTI BioPharma

3. Excludes \$82.5 million in potential additional deployment in milestones and options

A leading healthcare company focused on purchasing royalties on best-in-class therapeutics that treat serious medical conditions

Seasoned team of

specialized investment professionals with life science backgrounds and advanced business and scientific degrees

Disciplined capital allocation to growth

assets based on robust investment criteria that has resulted in 18% net IRRs over 16 years

Exceptional execution

from a kind database tracking over 6,500 royalties on over 2,000 drugs with in depth research and diligence



Track record of delivering growth and value

Drug Royalty I 2006 - 2008	Drug Royalty II 2009 - 2013	Drug Royalty III 2013 - 2018	DHT 2021 - present
19 New Royalties valued at	27 New Royalties valued at \$730M 1	15 New Royalties valued at	8 New Royalties & 1 Loan valued at up to
\$645M IRR	IRR	\$586M IRR	\$458M ² Current Yield ³
19%	18%	20%	>5%
	Simponi [®]	EYLEA SPINRAZA KEYTRUDA	Xenpozyme ⁻ SEMPAVELI [*] Zejulo OMIDRIA [*]

Consistent track record of efficient capital deployment at high returns


- 1. Includes \$82 million in capital deployed via co-investments through RMF 2 Co-Investment Fund
- Includes up to \$25 million in milestone payments for Vonjo, a \$21 million option to increase our exposure to Empaveli, a \$10 million milestone payment for Zejula, and \$26.5 million in milestone payments for Xenpozyme.
- 3. Does not include annual special dividend

Delivering on our long-term strategy

	At IPO	Today	2025 target
Capital deployment	\$650 – 750 million over 5 years	\$375 million deployed + \$82.5 million in milestones and options	Exceed top end of initial target range
Sustainable cash generation	Declining cash curve due to expected asset expiries	Flat to slightly growing cash flows through till 2025 without any new deals	7% - 9% annual royalty receipt growth
Portfolio duration	8 years	>9 years	>10 years
Capital resources	IPO proceeds and debt capacity	Attractive credit facilities with compounding effect of cash flows	Expanded credit facilities with compounding effect of cash flows

Focus on building long-term and sustainable strategic growth


Current deployment exceeds targets



Successful execution of IPO strategy

Industry requires significant cash for R&D

Worldwide Total Pharmaceutical R&D Spend (\$B)¹




Expected annual R&D expenditure in excess of \$350B across the life sciences value chain²

1. Source: Evaluate Pharma World Preview 2022, Outlook to 2028 15th edition, October 2022

DRIHEALTHCARE

 Pharma/biotech R&D spending has historically accounted for only 65% of the total, implying an overall annual spend including academic institutions of \$350 billion, growing over the next five years (source: Research America U.S. Investments in Medical Health Research and Development 2016-2020, January 2022)

Biotechs' limited cash reserves



70% of unprofitable NASDAQ-listed biotechs are estimated to have <2 years of cash

Tightening cash reserves highlight need to seek royalty-based financing

Source: Biocentury, Biotech Recovery: Status – Delayed, October 2022




State of the biotech market

Biotech IPOs¹ 16 120 14 100 12 80 Total Proceeds (\$B) Number of IPOs 10 8 6 40 4 20 2 0 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018 2020 2022 Total Proceeds — Number of IPOs

Rapid expansion of biotech market with >500 IPOs in last 10 years

Biotech Equities Performance²




Struggling equity capital markets for biotechs

Creates an environment where a large amount of capital is required, making DRI's royalty financing very attractive



10

Creating win-win deals for multiple counterparties




A proven and repeatable asset identification, selection and execution process

Proven track record of sourcing and closing accretive transactions

	Investment Thesis	Transaction Size
	High-quality oncology product with strong growth potential	\$110.0 million + \$25.0 million in potential milestones
Oracea	Dermatology product with existing commercial track record	\$50.5 million
§ EMPAVELI™	Hematology product with long-term horizon and attractive growth prospects	\$24.5 million + \$21.0 million option
Zejula	High-quality oncology product with multiple pipeline indications	\$35.0 million + \$10.0 million in potential milestone
OMIDRIA	Structured transaction on established product providing cash accretion	\$125 million
Xenpozyme™	Only approved product for ASMD with strong IP and long duration	\$30.0 million + \$26.5 million in potential milestones

Completed six transactions since IPO totaling up to \$458 million, with \$375 million deployed to date

Sustainable and efficient business model focused on cashflow % Sales of leading




Diversified portfolio generates significant cash to deploy to new royalties and investors

1. Adjusted EBITDA and Adjusted Cash Receipts are non-GAAP measures



Robust diversified portfolio



No individual product accounts for more than 24% of net book value



1. Based on net book value pro forma as at September 30, 2022

Last 12 months financial highlights




1. Total Cash Receipts and Adjusted EBITDA are non-GAAP measures and Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit are non-GAAP ratios.



Strong cash generation

Adjusted EBITDA for the Last Twelve Months Ended September 30, 2022 (\$M)¹



Cash available to drive portfolio growth and maintain distributions to unitholders


Adjusted EBITDA and Total Cash Receipts are non-GAAP financial measures. Adjusted EBITDA Margin is a non-GAAP ratio calculated as Adjusted EBITDA / Total Cash Receipts

2. The Net Change in Royalties Receivable and Interest Receivable and Interest receivable at the beginning of period, less royalties and interest receivable at the end of period, plus acquired royalties receivable and acquired cash royalty receipts included in the purchase price of the asset

uses are net of \$0.2 million related to board of trustee unit-based compensation and \$0.1 million related to amortization of


Adjusted Cash Earnings per Unit is a non-GAAP ratio, and is the sum of Adjusted Cash Earnings per Unit in each of the last four quarters, calculated as net earnings and other comprehensive earnings, plus: (i) amortization of royalty assets, (ii) impairment of royalty assets, (iii) amortization of 16 other current assets, (iv) unit-based compensation, and (v) board of trustees unit-based compensation, and less: (i) net gain (loss) on interest rate derivative, (ii) net gain (loss) on foreign exchange derivatives, (iii) non-cash royalty income, and (iv) non-cash interest income on loan receivable, divided by fully-diluted weighted average units outstanding

Deal structure case study: CTI Biopharma / Vonjo



Proven ability to provide flexibility in deal structuring while managing risk

Empaveli royalty transaction



Long-term horizon and attractive growth prospects

Zejula royalty transaction

TRANSACTION HIGHLIGHTS

\$35 Million up front purchase price

0.5% net royalty on worldwide net sales by GSK

Royalties collected on 1-quarter lag

STRONG GROWTH POTENTIAL

\$10 million milestone payment if Zejula is approved by FDA for the treatment of endometrial cancer by December 21, 2025


In development for metastatic castrate sensitive and resistant prostate cancer, endometrial cancer, HER2-breast cancer, and non-small cell lung cancer

Royalty term expected to continue for at least another 10 years world wide

Multiple indications in development represent a pipeline in a product


Zejula

Omidria royalty transaction



Substantial near-term cash flows with long-term structural growth

Xenpozyme royalty transaction



Long duration product with strong IP protection will generate high multiple on invested capital

Portfolio performance

(\$ thousands) Asset	Primary Marketer(s)	Therapeutic Area	Total Cash Royalty Receipts ^{1,2} LTM 9/30/22	Net Book Value 9/30/22
Asset	Printary Marketer(S)		LIW 9/30/22	9/30/22
G EMPAVELI [®]	Apellis	Hematology	-	24,036
EYLEA		Ophthalmology	13,547	24,492
FjuMist.Quadrivalent	AstraZeneca	Vaccine	3,128	2,803
% Natpara	Takeda	Endocrinology	2,684	21,240
OMIDRIA	Rayner	Ophthalmology	-	125,603
Oracea	SALDERMA GALDERMA	Dermatology	8,120	33,763
RYDAPT	U NOVARTIS	Oncology	10,403	9,775
SPINRAZA	Biogen	Spinal Muscular Atrophy	16,969	89,154
SCROV	СТЇ	Oncology	1,404	64,284
X enpozyme ^{**}	SANOFI 🌍	ASMD	-	30,000
Xolair	Roche U NOVARTIS	Respiratory	9,330	48,715
Zejula	gsk	Oncology	-	34,759
O Zytiga [,]	Johnson Johnson AstraZeneca	Oncology	17,978	19,444
Stelara' Simponi' ILATIS	Johnnen Johnnen 🌚 MERCK U NOVARTIS 🏑 Mitsubishi Tenabe	Autoimmune	4,893	4,363
Various			1,798	3,076
Total			90,254	535,507

DHT's assets have continued to show strong performance

- 1. Does not include Empaveli, Zejula, or Omidria royalties acquired in Q3 2022 for which the first cash royalty receipts will be received in Q4 2022 and Xenpozyme royalty acquired in Q4 2022 for which the first cash royalty receipts will be received in Q2 2023.
- 2. Total Cash Royalty Receipts is a non-GAAP measure.

Growth opportunities from existing assets

	Phase 1	Phase 2	Phase 3	Phase 4
Rydapt	• Rydapt + HDM201 in r/r AML with FLT mutation			
Nydapt	Rydapt + decitabine in unfit AML	patients		
	DEVC	DTE: Higher dose Spinraza		
Spinraza	ASCEND: Higher dose Sp	pinraza in patients who had received Evrysdi		
	RESPOND: Spinraza in patients who had received Zolgensma			
Zytiga	MAGNITUDE: Cor	mbination of Zytiga + Zejula in mCRPC		
	AMPLITUDE: Combination of Zytiga + Zejula in mHSPC			
Xolair		therapy or as adjunct therapy in food allergies		
Eylea	CANDELA: Higher dose Eylea in w			
		Higher dose Eylea in wet AMD and DME		
Vonjo		onfirmatory trial in Myelofibrosis		
		istrational trial in Geographic Atrophy		
Empaveli	DISCOVERY: Treatment for IgA Nephropathy, Lupu			
	PLAUDIT: Treatment for wAIHA			
		tage III/IV Ovarian Cancer with Dostarlimab		
	ZEST: tBRCAm HER2-negative BC or tBRCAwt TNBC who have detectable ctDNA after completion of definitive therapy			
Zejula		nt or Primary Advanced Endometrial Cancer with dost	arlimab	
		by in combination with pembrolizumab in NSCLC		
	AMPLITUDE: Con	nbination of Zytiga + Zejula in mHSPC		

Additional indications have potential to enhance royalty streams

Well capitalized for growth

\$20.5 million¹ Cash and cash equivalents

+

\$36.4 million¹ Royalties receivable

+

\$216.9 million^{1,2} Drawn on credit facilities



Significant capital available for deployment



As a September 30, 2022.
Does not include \$30 million drawn to fund Xenpozyme transaction.

Committed to best practices in ESG





Social

Accountability and integrity as core values

- Highly diverse and inclusive team
- Balanced gender representation
- Employee time off each quarter for charitable volunteering
- Professional development and career
- Corporate giving and donations



Governance

Valuing diversity and community support

- Best practice governance policies in place
- Diverse and majority independent Board
- Board oversight of ESG and risk management
- Active unitholder engagement
- Robust cybersecurity
- Whistleblower policy in place

Striving to deliver value to our stakeholders, our community, and society as a whole

DRIHEALTHCARE

our carbon footprint

Our key priorities



Execute on strong pipeline with a focus on long-term, sustainable growth generating strong unitholder returns

Invest in our people and build the industry leading royalty investment team

Operate at peak performance in all aspects of our business

DRIHEALTHCARE

Contact Us

Dave Levine ir@drihealthcare.com